Tweedy Browne Co LLC Sells 65 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Tweedy Browne Co LLC reduced its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.1% in the first quarter, according to its most recent filing with the SEC. The fund owned 66,699 shares of the pharmaceutical company’s stock after selling 65 shares during the quarter. Vertex Pharmaceuticals comprises approximately 1.3% of Tweedy Browne Co LLC’s holdings, making the stock its 15th largest holding. Tweedy Browne Co LLC’s holdings in Vertex Pharmaceuticals were worth $27,881,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Venturi Wealth Management LLC lifted its stake in shares of Vertex Pharmaceuticals by 1.1% in the 4th quarter. Venturi Wealth Management LLC now owns 2,293 shares of the pharmaceutical company’s stock valued at $933,000 after purchasing an additional 24 shares during the last quarter. Nicholas Hoffman & Company LLC. boosted its stake in Vertex Pharmaceuticals by 3.9% during the fourth quarter. Nicholas Hoffman & Company LLC. now owns 636 shares of the pharmaceutical company’s stock worth $259,000 after buying an additional 24 shares during the period. Hohimer Wealth Management LLC increased its position in Vertex Pharmaceuticals by 0.8% during the fourth quarter. Hohimer Wealth Management LLC now owns 2,932 shares of the pharmaceutical company’s stock valued at $1,193,000 after acquiring an additional 24 shares during the last quarter. Johnson Financial Group Inc. raised its stake in shares of Vertex Pharmaceuticals by 2.5% in the fourth quarter. Johnson Financial Group Inc. now owns 1,001 shares of the pharmaceutical company’s stock valued at $407,000 after acquiring an additional 24 shares during the period. Finally, Arthur M. Cohen & Associates LLC lifted its holdings in shares of Vertex Pharmaceuticals by 3.2% in the 4th quarter. Arthur M. Cohen & Associates LLC now owns 800 shares of the pharmaceutical company’s stock worth $326,000 after acquiring an additional 25 shares during the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs sold 7,073 shares of the firm’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $448.00, for a total value of $3,168,704.00. Following the completion of the transaction, the director now owns 40,000 shares in the company, valued at approximately $17,920,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CMO Carmen Bozic sold 2,280 shares of the firm’s stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $471.72, for a total transaction of $1,075,521.60. Following the completion of the transaction, the chief marketing officer now owns 30,099 shares of the company’s stock, valued at $14,198,300.28. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Bruce I. Sachs sold 7,073 shares of the company’s stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $448.00, for a total transaction of $3,168,704.00. Following the completion of the sale, the director now directly owns 40,000 shares in the company, valued at $17,920,000. The disclosure for this sale can be found here. In the last quarter, insiders have sold 28,366 shares of company stock worth $13,058,787. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Stock Down 0.6 %

NASDAQ VRTX traded down $3.17 on Friday, hitting $488.96. The stock had a trading volume of 273,643 shares, compared to its average volume of 1,211,515. The business’s fifty day moving average price is $459.28 and its 200 day moving average price is $431.15. The stock has a market cap of $126.18 billion, a price-to-earnings ratio of 31.94, a price-to-earnings-growth ratio of 2.55 and a beta of 0.39. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.50 and a quick ratio of 3.29. Vertex Pharmaceuticals Incorporated has a 52-week low of $340.20 and a 52-week high of $496.62.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.66 by $1.10. The company had revenue of $2.69 billion for the quarter, compared to analyst estimates of $2.58 billion. Vertex Pharmaceuticals had a return on equity of 23.08% and a net margin of 39.46%. The firm’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same period in the prior year, the company posted $2.67 EPS. Equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Wells Fargo & Company upped their target price on Vertex Pharmaceuticals from $540.00 to $555.00 and gave the company an “overweight” rating in a research note on Monday, June 24th. Oppenheimer reaffirmed an “outperform” rating and issued a $500.00 price objective on shares of Vertex Pharmaceuticals in a research report on Monday, April 15th. Royal Bank of Canada decreased their target price on Vertex Pharmaceuticals from $424.00 to $421.00 and set a “sector perform” rating for the company in a research report on Tuesday, June 11th. Piper Sandler raised their price target on shares of Vertex Pharmaceuticals from $450.00 to $456.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 7th. Finally, Morgan Stanley lifted their price objective on shares of Vertex Pharmaceuticals from $402.00 to $455.00 and gave the company an “equal weight” rating in a report on Thursday. Three analysts have rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $452.57.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.